In the midst of expanded development and marketing of products
containing cannabis and cannabis-derived compounds, President
Donald Trump's FY 2021 proposed budget includes an additional $5
million for the U.S. Food and Drug Administration (FDA) to
undertake greater regulatory and enforcement activities regarding
these products.
Specifically, the budget says, "This new funding will
enable FDA to continue regulating the usage of cannabis-derived
substances, such as cannabidiol (CBD), in FDA-regulated products
such as dietary supplements and when used as unapproved food and
feed additives. The initiative will support regulatory activities,
including developing policy, and continue to perform its existing
regulatory responsibilities including review of product
applications, inspections, enforcement, and targeted
research."